Compare WVE & AIIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WVE | AIIR |
|---|---|---|
| Founded | 2012 | N/A |
| Country | Singapore | United Arab Emirates |
| Employees | 317 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Tobacco |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2015 | N/A |
| Metric | WVE | AIIR |
|---|---|---|
| Price | $6.04 | $6.07 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 16 | 0 |
| Target Price | ★ $29.81 | N/A |
| AVG Volume (30 Days) | ★ 2.2M | 10.0K |
| Earning Date | 04-28-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,704,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $85.67 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 149.43 | N/A |
| 52 Week Low | $5.02 | $5.29 |
| 52 Week High | $21.73 | $8.15 |
| Indicator | WVE | AIIR |
|---|---|---|
| Relative Strength Index (RSI) | 53.05 | 46.13 |
| Support Level | $5.49 | $5.29 |
| Resistance Level | $6.21 | $6.62 |
| Average True Range (ATR) | 0.25 | 0.67 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 83.54 | 38.36 |
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
AIR Global PLC operates in the social inhalation products sector and has operations across multiple international markets. Its portfolio includes businesses and products related to shisha and hookah, including flavored shisha molasses, hookah and shisha e-commerce platforms, and charcoal-free shisha devices. The company also conducts product research and testing in partnership with independent laboratories to support the development of inhalation-related products and technologies.